NCT06945484 PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study
| NCT ID | NCT06945484 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Utah |
| Condition | NSCLC Stage II |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-11-21 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-11-21 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage II-III primary lung cancer patients receiving multimodal therapy, and delivered through telehealth.
Eligibility Criteria
Inclusion Criteria: * Ages 18 and older at time of diagnosis * Patient diagnosed with stage II and III non-small cell lung cancer (NSCLC) * Patient receives either neoadjuvant chemotherapy or immunotherapy and surgery * Patient able to follow direction and complete questionnaires in English or Spanish * Patient agrees to complete the PERCC intervention Exclusion Criteria: * Morbidly obese (BMI \>40 kg/m2 ) or anorexic (BMI \<17.5 kg/m2 ) * Abnormalities on screening physical exam per study physicians or physical therapist to contraindicate participation in exercise program compliance * Alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer) * Patient scheduled to receive single modality cancer treatment (unimodal therapy), scheduled to begin treatment within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started
Contact & Investigator
Cornelia Ulrich, MS, PhD
PRINCIPAL INVESTIGATOR
Huntsman Cancer Institute/ University of Utah
Frequently Asked Questions
Who can join the NCT06945484 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying NSCLC Stage II. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06945484 currently recruiting?
Yes, NCT06945484 is actively recruiting participants. Contact the research team at thomas.varghese@hsc.utah.edu for enrollment information.
Where is the NCT06945484 trial being conducted?
This trial is being conducted at Galveston, United States, Salt Lake City, United States.
Who is sponsoring the NCT06945484 clinical trial?
NCT06945484 is sponsored by University of Utah. The principal investigator is Cornelia Ulrich, MS, PhD at Huntsman Cancer Institute/ University of Utah. The trial plans to enroll 20 participants.